About Clearside Biomedical, Inc.
https://www.clearsidebio.comClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
CEO
George M. Lasezkay Pharm.D., Pharma.D.
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-09-15 | Reverse | 1:15 |
Most Recent Analyst Grades
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Chardan Capital
Neutral
HC Wainwright & Co.
Neutral
Needham
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ACT CAPITAL MANAGEMENT, LLC
Shares:2.2M
Value:$2.2M
BLACKROCK INC.
Shares:798.14K
Value:$798.14K
BLACKROCK FUND ADVISORS
Shares:551.17K
Value:$551.17K
Summary
Showing Top 3 of 25
About Clearside Biomedical, Inc.
https://www.clearsidebio.comClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $201K ▼ | $7.24M ▲ | $-5.97M ▼ | -2.97K% ▼ | $-1.14 ▼ | $-3.32M ▼ |
| Q2-2025 | $492K ▼ | $3.98M ▼ | $-4.5M ▲ | -913.62% ▼ | $-0.87 ▲ | $-1.65M ▲ |
| Q1-2025 | $2.33M ▲ | $7.29M ▼ | $-8.22M ▼ | -352.92% ▲ | $-1.65 ▼ | $-4.75M ▼ |
| Q4-2024 | $306K ▼ | $7.31M ▲ | $-7.31M ▲ | -2.39K% ▼ | $-1.44 ▲ | $-4.65M ▲ |
| Q3-2024 | $1.04M | $6.97M | $-7.69M | -740.66% | $-1.5 | $-5.16M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.8M ▼ | $11.64M ▼ | $65.59M ▲ | $-53.95M ▼ |
| Q2-2025 | $9.38M ▼ | $15.33M ▼ | $64.07M ▼ | $-48.73M ▼ |
| Q1-2025 | $13.63M ▼ | $19.67M ▼ | $65.58M ▲ | $-45.91M ▼ |
| Q4-2024 | $20.02M ▼ | $25.13M ▼ | $63.98M ▲ | $-38.85M ▼ |
| Q3-2024 | $23.59M | $29.16M | $63.95M | $-34.79M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.97M ▼ | $-5.48M ▼ | $0 | $2.9M ▲ | $-2.58M ▲ | $-5.48M ▼ |
| Q2-2025 | $-4.5M ▲ | $-4.73M ▲ | $0 ▲ | $477K ▲ | $-4.25M ▲ | $-4.73M ▲ |
| Q1-2025 | $-8.22M ▼ | $-5.83M ▼ | $-9K ▼ | $-553K ▼ | $-6.39M ▼ | $-5.83M ▼ |
| Q4-2024 | $-7.31M ▲ | $-5.25M ▲ | $9.31M ▲ | $2.08M ▲ | $6.13M ▲ | $-5.7M ▲ |
| Q3-2024 | $-7.69M | $-5.91M | $1.55M | $14K | $-4.35M | $-5.97M |
Revenue by Products
| Product | Q1-2019 | Q2-2019 | Q3-2019 | Q2-2020 |
|---|---|---|---|---|
 License And Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
George M. Lasezkay Pharm.D., Pharma.D.
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-09-15 | Reverse | 1:15 |
Most Recent Analyst Grades
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Chardan Capital
Neutral
HC Wainwright & Co.
Neutral
Needham
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
ACT CAPITAL MANAGEMENT, LLC
Shares:2.2M
Value:$2.2M
BLACKROCK INC.
Shares:798.14K
Value:$798.14K
BLACKROCK FUND ADVISORS
Shares:551.17K
Value:$551.17K
Summary
Showing Top 3 of 25